+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

Visiongain Publishes Biosimilar Monoclonal Antibodies Market Report 2022-2032

25 July 2022
Pharma

Visiongain has published a new report entitled Biosimilar Monoclonal Antibodies Market Report 2022-2032: Forecasts by Type (Synthetic Chemicals, Biopharmaceuticals), by Application (Chronic & Autoimmune Diseases, Oncology Diseases, Other), by Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis.

The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a CAGR of 23.5% during the forecast period 2022-2032.

Biosimilars Companies Must Address R&D Infrastructure Across Emerging Economies
In several emerging economies, research & development infrastructure problems must be resolved by biosimilars companies. Manufacturers may be concerned about intermittent power and refrigeration in remote areas because so many biosimilars necessitate cold storage logistics and storage. It is already common practice in the small-molecule industry to build formulations for new markets using the expertise of regional manufacturers. The complexity of the production process makes this difficult for biologics, however, regional partnerships might have an even greater impact given the more difficulties with immunogenicity & stability with large molecules.

How Has COVID-19 Had a Significant Impact on the Biosimilar Monoclonal Antibodies Market?
Biopharmaceutical manufacturers are finding it difficult to predict the enormous imbalance between supply and demand brought on by COVID-19. On the supply side, lockdowns around the world had caused disruptions in supply chain operations and production in centers like China, India, and the United States. On the one hand, patients are put off looking for therapy, especially for less practical delivery techniques like infusions, which might result in a decline in patient volume and total demand. Although all producers are attempting to reduce the possibility of supply shortages, biosimilar manufacturers who depend on facilities in Europe and Asia may be particularly vulnerable in terms of supply.

How will this Report Benefit you?
Visiongain’s 461-page report provides 238 tables and 272 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses of the global biosimilar monoclonal antibodies market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Biosimilar Monoclonal Antibodies. Get financial analysis of the overall market and different segments including type, application, compound, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing biosimilar monoclonal antibodies market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Biosimilars: Leading the Way to Cost-Effective Healthcare
Drugs known as "biosimilars" are identical copies of extremely complex biological medicines that work in the same way as the original therapy. The US FDA is approving an increasing number of biosimilars. This promotes competition, which can lower overall healthcare costs, especially when treating diseases like chronic & autoimmune diseases, oncology diseases, and other applications. On 4th May 2022, The US Food and Drug Administration authorized Trastuzumab, a biosimilar drug created by Mylan and Biocon. Trastuzumab (Ogivri) is a biosimilar drug of Roche's popular drug Herceptin, a widely used and acknowledged therapy for the treatment of breast cancer.

mABs Products Will Continue to be a Dominant Therapeutic Modality
In the near future, mABs products will continue to be crucial in the management of numerous disorders. The effect of mAB therapies on efforts to develop COVID-19 vaccine treatments is unknown. Despite the present epidemic, it is projected that worldwide mABs authorization and sales would rise over the next five years. While initially hurting mABs originator revenues, the introduction of biosimilar products is predicted to boost overall access to various antibody product types. As a result, this sector of the biopharmaceutical industry will see a net rise in patients. Manufacturing capacity is always growing to keep up with the increased demand for these commodities.

Where are the Market Opportunities?

Local Firms Can Assist International Biosimilars Companies in Increasing Sales
Local businesses can help multinational biosimilars companies grow their sales by introducing stakeholders, providing some local credibility, and being knowledgeable of local operating environments and patient expectations. This is in addition to the strength of the biosimilars company's worldwide brand. A lot of developing nations are passing local manufacturing regulations that demand that a product be produced (at least partially) domestically. Partnership with local companies could be a flexible and affordable way to do this while also supporting foreign firms in overcoming obstacles like local laws and customs. Numerous recent partnerships (such as Lilly's strategic collaboration with Chinese pharmaceutical company Innovent and South Korean company Hanmi Pharmaceuticals on 27th March 2022) have shown that multinational biosimilars enterprises can profit from and use resident players' R&D capabilities.

Untapped Opportunities Across Emerging Economies
Lack of regulatory oversight and/or adherence, immature distribution networks, subpar healthcare insurance infrastructures, fragmented demand, and producer margin pressure may all be factors limiting the growth of emerging markets. As a result, businesses might need to alter their current sales, advertising, and distribution strategies. Infrastructure and market access are two significant issues that must be resolved. Biosimilars manufacturers will need widespread access to local companies, distributors, and retailers if they want to succeed in untapped and emerging markets of developing countries. To develop evidence-based reimbursement plans, manufacturers will need to work closely with payers and legislators. As purchasing power and the demand for biopharmaceuticals rise, governments and payers in emerging economies face the challenge of limiting healthcare costs.

Competitive Landscape
The major players operating in the biosimilar monoclonal antibodies market are 3SBio Inc., AbbVie Inc. (AbbVie), Amgen Inc., BIOCAD, Biocon Limited, Boehringer Ingelheim, Celltrion Healthcare Co Ltd., Dong-A Socio Holdings, Dr. Reddy’s Laboratories Ltd, Genor Biopharma Holdings Ltd., Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc. (Pfizer), Reliance Life Sciences, Torrent Pharmaceuticals Limited. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launches.

Recent Developments
• On 8th March 2022, In Holly Springs, North Carolina, Amgen announced the construction of its newest biomanufacturing facility. By 2025, the facility should be operational, helping to meet the rising demand for Amgen's medications, which are used to treat life-threatening conditions like cancer and heart disease.
• On 28th Feb 2022, Biocon Biologics Ltd., a division of Biocon Ltd., disclosed a binding contract with its business partner Viatris Inc. In order to establish a distinctive, fully integrated, global biosimilars organization, Biocon Biologics Ltd. (BBL) will thus purchase Viatris' biosimilars business. Up to US$3 billion in total consideration will be given to Viatris, consisting of over US$2 billion in cash and US$1 billion in Compulsorily Convertible Preference Shares (CCPS) in BBL.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Stem Cell Technologies and Applications Market Report 2022-2032

The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.

01 December 2022

Read

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2023-2033

The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.

01 December 2022

Read

Visiongain Publishes Medical Imaging Market Report 2022-2032

The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.

30 November 2022

Read

Visiongain Publishes Antibody Drug Conjugates Market Report 2022-2032

The global antibody drug conjugates market was valued at US$3,668 million in 2021 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

28 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever